Article

The Problem with the Cancer ‘Battle’

The terminology surrounding the cancer journey is often associated with a “battle” and can misconstrue the experience of treatment.

Language is an important tool when it comes to living with cancer. The terminology used when referring to an individual’s experience with the disease can incite a range of emotions and can often be misconstrued.

Dr. Mark Lewis, of Intermountain Healthcare, is also a survivor. In a recent interview with CURE®, Lewis discussed why the use of the word “battle” can be polarizing when referring to someone’s cancer journey, and why sometimes the idea of opting to forego treatment is the bravest decision of all.

Transcription:

One of the problems I have with language around cancer is, whether patients choose or not, there's often a lot of talk about ‘battle.’

In fact, in almost every obituary I saw about Chadwick Boseman mentioned him battling cancer. You know, if you accept the fighting metaphor, that's great, but it's not for everybody. And what I don't like about it is it implies some lack of courage, or spirit, when patients either die, or, quite reasonably sometimes, if they choose not to pursue chemotherapy.

Sometimes I think the bravest decision I see is someone who, against the recommendation and pressure from their family, says, ‘You know what, I've listened to you, doc, I've heard about the risks and benefits. I just want to live my life, however long that's going to be, and I want to maximize its quality.’

That, in itself, is a very courageous decision, in my opinion.

Related Videos
Image of woman with black hair.
Image of doctor with brown hair.
Image of man with black hair.
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Related Content